Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand(Novartis (Switzerland)), Raj Tummala(Hofstra University), Ian N Bruce(University of Manchester), Philip Z. Brohawn(Hofstra University), Christophe Richez(Centre National de la Recherche Scientifique), Anna Berglind(Hofstra University), Richard Furie(Hofstra University), Anca Askanase(Columbia University Irving Medical Center), Yoshiya Tanaka(University of Occupational and Environmental Health Japan), Lilia Pineda(Hofstra University), Sang‐Cheol Bae(Unknown)
Cited by 1,318
Related Papers
Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis
|Nature Genetics|2012|960
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726